- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 369KB)
Olaparib – November 2023
Olaparib (breast cancer): Tablet 100 mg, Tablet 150 mg; Lynparza®
Last updated
1 March 2024